The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints.
 
Benjamin Louis Maughan
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Peleton; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Andrew W Hahn
No Relationships to Disclose
 
Roberto Nussenzveig
Consulting or Advisory Role - Tempus
 
John Hoffman
Research Funding - Blue Earth Diagnostics (Inst); GE Healthcare (Inst)
 
Kathryn Morton
No Relationships to Disclose
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Viralytics (Inst)
 
Julia Anne Batten
No Relationships to Disclose
 
Jared Thorley
No Relationships to Disclose
 
Josiah Hawks
No Relationships to Disclose
 
Victor Sacristan Santos
No Relationships to Disclose
 
Gayatri Nachaegari
No Relationships to Disclose
 
Xuechen Wang
No Relationships to Disclose
 
Kenneth M. Boucher
No Relationships to Disclose
 
Benjamin Haaland
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Lilly; Lilly; Medivation/Astellas; Nektar; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)